Angiogenesis, Chemotherapy Effect, Small Cell Lung Cancer
Conditions
Brief summary
To evaluate the clinical efficacy and safety of surufatinib combined with irinotecan in the second line treatment of small cell lung cancer.
Detailed description
According to the inclusion and exclusion criteria, 40 patients with small cell lung cancer who failed to receive standard first-line therapy were selected to evaluate the efficacy and safety of surufatinib combined with irinotecan in the second-line treatment of small cell lung cancer.
Interventions
DRUGSurufatinib
250 mg/day p.o. QD
DRUGIrinotecan
Participants will receive irinotecan，100 mg/m2，Intravenous drip, day 1 and day 8 of every 3 weeks
Sponsors
Fujian Cancer Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age ≥18 years; Volunteer to participate in the trial and sign informed consent; * Small cell lung cancer diagnosed by histopathology; * Previous failure to receive first-line standard treatment was defined as intolerable toxic and side effects, disease progression during treatment, or recurrence after treatment; Intolerability was defined as grade IV (thrombocytopenia grade III and above) for hematologic toxicity and grade III or above for nonhematologic toxicity. Note: Each line of drug refers to medication for at least 1 cycle regardless of single drug or multi-drug combination; * ECOG score: 0-1; * At least one lesion detectable by CT, according to RECIST 1.1; * Expected survival ≥12 weeks; * At least one measurable lesion (RECIST 1.1 criteria, see Appendix 2); * The functions of major organs and bone marrow are basically normal: * Blood routine: white blood cell ≥ 4.0 x 109/L, neutrophil ≥ 1.5 x 109/L, platelet ≥ 100 x 109/L, hemoglobin ≥ 90 g/L; A) International normalized ratio (INR) ≤1.5× upper limit of normal (ULN), and activated partial thromboplastin time (APTT) ≤1.5×ULN; B) Liver function: total bilirubin ≤ 1.5 x ULN; In the absence of liver metastasis, ALT/AST /ALP ≤ 2.5 x ULN; ALT/AST /ALP ≤ 5 x ULN in patients with liver metastasis; C) Renal function: serum creatinine ≤ 1.5 x ULN, and creatinine clearance (CCr) 60 mL/min (see Appendix 6); D) Normal cardiac function, left ventricular ejection fraction (LVEF) ≥ 50% by two-dimensional echocardiography. * Brain metastases must have been asymptomatic or treated and stabilized after discontinuation of steroids and anticonvulsants for at least 1 month prior to study treatment; * Patients of childbearing age (including female and female partners of male patients) must take effective birth control measures; * Good compliance is expected, and the efficacy and adverse reactions can be followed up according to the protocol requirements.
Exclusion criteria
* Small cell lung cancer with other pathological types of tumors; * Previously received anti-angiogenic drugs, including bevacizumab, sovanitinib, sunitinib, sorafenib, anlotinib, apatinib, etc. * Receive the following treatments within the first 4 weeks of treatment, including but not limited to surgery, chemotherapy, radical radiotherapy, biotargeted therapy, immunotherapy, and other investigational drugs; * Pregnant or lactating women; * With pleural effusion or ascites, respiratory syndrome (≥CTC AE grade 2 dyspnea); * Symptomatic brain or meningeal metastases (except those who have undergone local radiotherapy or surgery for brain metastases for more than 6 months and have stable disease control); * Severe infection (e.g., intravenous infusion of antibiotics, antifungals, or antivirals) within 4 weeks prior to treatment, or unexplained fever \> 38.5 ° C during screening/initial administration; * Hypertension that is not well controlled with antihypertensive medication (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg) * The urine routine indicated urinary protein ≥2+, and 24-hour urinary protein quantity \>1.0g; * Obvious clinical bleeding symptoms or obvious bleeding tendency within 3 months before treatment (bleeding \> 30 mL within 3 months, hematemesis, melanism, blood in stool), hemoptysis (fresh blood \> 5 mL within 4 weeks), etc. Or treatment for a venous/venous thrombotic event in the previous 6 months, such as a cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism; Long-term anticoagulant therapy with warfarin or heparin or long-term antiplatelet therapy (aspirin ≥300 mg/day or clopidogrel ≥75 mg/day) is required; * Active heart disease, including myocardial infarction and severe/unstable angina, developed 6 months before treatment. Echocardiography showed left ventricular ejection fraction \< 50% and poor arrhythmia control (including QTcF interval, \> 450 ms in men and \> 470 ms in women). * The patient had had other malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix) within the previous 3 years or at the same time. * Known allergy to the study drug or any of its excipients; * Active or uncontrolled severe infections; 1. Known human immunodeficiency virus (HIV) infection; 2. A known history of clinically significant liver disease, including viral hepatitis \[known hepatitis B virus (HBV) carriers must exclude active HBV infection, i.e., HBV DNA positivity (\>1×104 copies /mL or \>2000 IU/ mL); 3. Known hepatitis C virus infection (HCV) and HCV RNA positive (\>1×103 copies /mL), or other hepatitis, liver cirrhosis\]; * Any other disease, with clinical significance of metabolic abnormalities, abnormal physical examination or laboratory abnormalities, according to researchers, there is reason to suspect the patient has not suitable for the use of study drugs of a disease or condition (such as have a seizure and require treatment), or will affect the interpretation of results, or to make patients in high-risk situations; * Other conditions deemed inappropriate for inclusion by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months | PFS was defined as the time from randomization until the date of first occurrence of investigator-assessed radiological disease progression or death due to any cause, whichever came first. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective remission rate (ORR) | up to 12 months | Refers to the proportion of patients whose tumors have shrunk to a certain amount and kept for a certain time, including cases of complete remission and partial remission. |
| Disease control rate | up to 12 months | The percentage of patients with complete response, partial response, and stable disease for more than 4 weeks in whom response could be evaluated. |
| Overall survival（OS） | From date of randomization until the date of death from any cause, whichever came first, assessed up to 100 months | OS was defined as the time from the date of randomization to the date of death due to any cause. For subjects who were alive or lost to follow-up by the data analysis cut-off date, survival was censored at the subject's last known survival time. |
Contacts
Primary ContactZhiyong He
Backup ContactMeifang Li
Outcome results
None listed